Sareum is an experienced and specialist Structure-based Drug Discovery company. We accelerate and improve the productivity of both our in-house and our partners' discovery research using our proprietary approaches.

Sareum has a highly experienced team with a track record of delivering high quality results for pharmaceutical and biotechnology clients.

Sareum is developing a robust pipeline of novel cancer drug candidates for partnering with pharmaceutical companies. We generate revenues to support this pipeline through the provision of our specialist discovery research services.

Sareum delivers results through the entire drug discovery value chain, from gene through to valuable preclinical candidate. We carry out complete structure-based discovery programmes for creating novel pre-clinical candidates as well as specific tailored projects to resolve clients' issues in gene to structure, structure to lead, and/or lead to candidate activities.

Sareum creates novel IP and highly valuable clinical candidates for our clients across a range of therapeutic areas. We are very flexible in our approach to how we structure our partnerships and can engage in fee-for-service, out-source research, technology transfer or joint research programmes.

Sareum is a public listed company and its shares are listed on the AIM market of the London Stock Exchange.

136% rise. Not bad for a dead dog! :o)

Far from a dead dog 'kimoldfield' imhho. This is a discovery drug company on the verge transformational findings. Watch this space dor double digit figures. dyor

They have had a very chequered history superman, promise after promise, most of them broken but like you I don't think it can remain in the dead dog category! I think they may have at last turned the corner, revenues ahead and looking quite good.

Income! :o)


Milestone Payment from Chk1 Licence Agreement

RNS

RNS Number : 6485T
Sareum Holdings PLC
09 January 2017

(AIM: SAR)

9 January 2016

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Milestone Payment from Chk1 Licence Agreement

Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development company, is pleased to announce the attainment of a US$2.0 million success milestone payment as part of the Chk1 licence agreement between its co-investment partner, the CRT Pioneer Fund, and Sierra Oncology, Inc. (NASDAQ: SRRA), formerly, until today, ProNAi Therapeutics, Inc.

Under the terms of the agreement, first announced on 27 September 2016, the fee has become payable as a result of the successful transfer of the two ongoing Phase 1 clinical trials to Sierra Oncology. Further payments in the aggregate amount of up to US$319.5 million may additionally become payable upon achievement of certain development, regulatory and commercial milestones. Sierra Oncology will also pay high single to low double digit royalties on the net sales of any product successfully developed.

Under Sareum's agreements with Cancer Research Technology and the CRT Pioneer Fund, Sareum is entitled to 27.5% of all payments arising from the Chk1 licence agreeement. Therefore, Sareum will receive $550,000 as its financial share of this milestone event.

Furthermore, the unspent balance, now estimated at c£200,000, of the financial commitment to the trial funding of £797,500 made by Sareum in December 2015 will be returned to the Company in due course.

Dr Tim Mitchell, CEO of Sareum commented, "We are delighted that the first milestone event from this agreement has been reached. This is a useful addition to our cash position, following the receipt of £1.5 million as our share of the $7 million up-front payment announced in September."

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014.